Without prejudice
OPINION
Professor of Oncology, Angus, Dalgleish; gives vital information on a repurposed drug he uses for his cancer patients, given at a very low dose. This is Low Dose Naltrexone.
Naltrexone at low doses (LDN) and its relevance to cancer therapy
Naltrexone was designed to inhibit opioid receptors without activating them and hence used to block the stimulatory effects of morphine and heroin. It was noted that in certain patients being treated with naltrexone for an opioid addiction many reported significant secondary benefits when being weaned off naltrexone. This group of patients had chronic inflammatory and autoimmune conditions and reported improvements whilst using the lower dosages of naltrexone. There have also been recent anecdotal reports of cancer resolution following the use of low doses of naltrexone (LDN). However, the mechanism of action is unclear.
AREAS COVERED
We review three mechanisms through which LDN can influence cancer progression; namely, (a) antagonism of receptors to which LDN binds, which include toll-like receptors 7–9 that led to IL-6 suppression b) modulation of immune function in patients; and c) direct inhibition of signaling pathways involved in cancer cell control, including the priming of pro-apoptotic pathways.
EXPERT OPINION
Considering the increase in the number of anecdotal reports of activity, there will likely be a bigger drive toward using LDN in the oncological setting. These reports support clinical trials of LDN in cancer, especially when given in combination with certain chemotherapy.
THIS IS LOW DOSE NALTREXONE.
Resources:
Check out the LDN trust website for much more, The LDN 2025 Conference 6th - 8th June 2025 ldnresearchtrust.org
Naltrexone at low doses (LDN) and its relevance to cancer therapy. Expert Rev Anticancer Ther, 22 (3). pp. 269-274. ISSN 1744-8328 SGUL Authors: Liu, Wai Man Dalgleish, Angus George DOI:10.1080/14737140.2022.2037426
Naltrexone at low doses (LDN) and its relevance to cancer therapy (e print 114135) SGUL (St George's University of London) Liu, WM; Dalgleish, AG (2022) ePrint HERE
Acknowledgement Original Sources
Media Segment Credit to YT-user: | YT-handle: @Campbellteaching | YT-tagline: Cheap repurposed drug | YT-clip: Whho0mboPAA | YT-date-(AWST): 2025 MAY 03 | 4CM-notes: 2025 MAY 03 Dr John Cambell w Prof of Oncology, Angus Dalgleish talk Low Dose Naltrexone curing cancer sufferers.mp4
Share this post